GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (OTCPK:ORGS) » Definitions » Operating Margin %

ORGS (Orgenesis) Operating Margin % : -2,196.25% (As of Sep. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Orgenesis Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Orgenesis's Operating Income for the three months ended in Sep. 2024 was $-7.62 Mil. Orgenesis's Revenue for the three months ended in Sep. 2024 was $0.35 Mil. Therefore, Orgenesis's Operating Margin % for the quarter that ended in Sep. 2024 was -2,196.25%.

Warning Sign:

Orgenesis Inc operating margin has been in a 5-year decline. The average rate of decline per year is -38.1%.

The historical rank and industry rank for Orgenesis's Operating Margin % or its related term are showing as below:

ORGS' s Operating Margin % Range Over the Past 10 Years
Min: -10356.79   Med: -179.54   Max: -20.93
Current: -5649.39


ORGS's Operating Margin % is ranked worse than
88.03% of 1011 companies
in the Biotechnology industry
Industry Median: -162.31 vs ORGS: -5649.39

Orgenesis's 5-Year Average Operating Margin % Growth Rate was -38.10% per year.

Orgenesis's Operating Income for the three months ended in Sep. 2024 was $-7.62 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 was $-50.79 Mil.

Warning Sign:

Orgenesis Inc had lost money in 92% of the time over the past 12quarters.


Orgenesis Operating Margin % Historical Data

The historical data trend for Orgenesis's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Operating Margin % Chart

Orgenesis Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -563.61 -1,251.71 -40.90 -20.93 -10,356.79

Orgenesis Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,031.82 -17,981.21 -6,333.33 -1,856.91 -2,196.25

Competitive Comparison of Orgenesis's Operating Margin %

For the Biotechnology subindustry, Orgenesis's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Orgenesis's Operating Margin % falls into.



Orgenesis Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Orgenesis's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-54.891 / 0.53
=-10,356.79 %

Orgenesis's Operating Margin % for the quarter that ended in Sep. 2024 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=-7.621 / 0.347
=-2,196.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orgenesis  (OTCPK:ORGS) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Orgenesis Operating Margin % Related Terms

Thank you for viewing the detailed overview of Orgenesis's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis Business Description

Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies.
Executives
Jacob Safier 10 percent owner C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004
Elliot Maltz officer: Chief Financial Officer C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Efrat Assa Kunik officer: Chief Development Officer C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
David Sidransky director JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Mario Philips director C/O ATMI, INC, DANBURY CT 06810
Sarah Ferber officer: Chief Scientific Officer 17B HAHASKALA STREET, TEL AVIV L3 67890
Guy Yachin director 7 ORCHARD WAY N, POTOMAC MD 20854
Yaron Adler director 4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710
Vered Caplan officer: CEO 20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280
Universite Libre De Bruxelles 10 percent owner AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050
Olivier Belenger 10 percent owner DIEWEG, 69, BRUSSELS C9 1070
Ii Sa Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Sca Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Denis Bedoret officer: See Remarks 48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041
Ashish Nanda director 2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452